ONA-389 / Ona Therap - LARVOL DELTA

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types (PRNewswire) - "Its lead ADC, ONA-255, has broad potential to treat breast, gastric, and other solid tumors, and is advancing through IND-enabling studies to initiate clinical development by the end of 2025. In parallel, Ona is developing ONA-389, a second ADC that is positioned for the treatment of advanced microsatellite stable (MSS) colon and liver cancers. This promising therapeutic is set to begin IND-enabling studies in the second half of 2025."

New trial • Breast Cancer • Colon Cancer • Gastric Cancer • Hepatocellular Cancer